Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening
ConditionGlioblastoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMedical University of Vienna
About this trial
Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.
Eligibility criteria
Qualifiers
Age 18-75
ECOG performance status 0-2
Newly diagnosed glioblastoma, IDH wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System
MGMT promotor unmethylated per local investigator
Disqualifiers
Current participation in another therapeutic clinical trial
Patients with a concurrent malignancy or malignancy within five years prior of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years
Pregnant or lactating women
Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody [HBsAg] test and a positive anti-hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
Trial design
Treatments tested in this trial
- CBMed Drug Screening Plattform
Treatment groups
240 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov